PLAU and familial pancreatic carcinoma: These earlier results were confirmed by this study: six out of the eight nanobiosensors tested demonstrated significant differences between both pancreatic cancer groups and the healthy control group, which indicated that these are promising candidates for pancreatic cancer detection (cathepsin B, MMP1, −3, −9, neutrophil elastase, and uPA)15.